Please login to the form below

Not currently logged in
Email:
Password:

Novartis receives Rasilez approval in China

Novartis has received regulatory approval for its high blood pressure treatment Rasilez in China

Novartis has received regulatory approval for its high blood pressure treatment Rasilez (aliskiren) in China. The first-in-class direct renin inhibitor is approved for use as a treatment on its own, as well as in combination with other high blood pressure medication.

Rasilez is already approved in 80 countries and is known as Tekturna in the US.  It works by directly inhibiting the activity of renin, an enzyme produced by the kidneys that can cause blood vessels to narrow. This can then lead to high blood pressure.

"We are pleased that our continued investment in China enables us to bring treatment options to patients that address the needs of this growing market," said David Epstein, division head of Novartis Pharmaceuticals. "By adapting our development timelines for Rasilez we have been able to provide patients in China with timely access to this novel therapy for high blood pressure."

According to Novartis, high blood pressure is the "leading preventable cause of death in China" with two million deaths attributed to the condition occurring there each year. Around 153 million adults in the country are thought to be affected by the condition currently, with 76 per cent of patients not being treated to an optimum level, according to 'Premature Deaths Attributable to Blood Pressure in China: A Prospective Cohort Study', published in The Lancet.

Speaking on the approval, Dr Yong Huo, president-elect of the Chinese Society of Cardiology, Department of Cardiology, Peking University First Hospital, said: “Modifications in lifestyle and diet have led to high blood pressure becoming a significant and growing problem in China.

"Because the disease has no apparent symptoms, awareness as well as treatment and control of the condition are very low. As a result, there is a clear need for innovative high blood pressure treatments in China to enable more patients to successfully manage their condition."

20th July 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Page & Page

Page & Page is a new kind of marketing communications consultancy. We change beliefs and behaviours to improve health outcomes...

Latest intelligence

The relevance of patient perspectives to value
Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
How is the NHS Long-term Plan being put into action?
Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...
real world studies
The evolution of real-world studies
How industry and regulators are using real-world data...

Infographics